28.4 C
New York
Thursday, August 18, 2022
HomeBusiness NewsMobileye N.V. (NYSE:MBLY) Proposing Of 17,127,000 Ordinary Shares- Novartis AG (NYSE:NVS), Rovi...

Mobileye N.V. (NYSE:MBLY) Proposing Of 17,127,000 Ordinary Shares- Novartis AG (NYSE:NVS), Rovi Corporation (NASDAQ:ROVI)

Date:

Related stories

Silicon Valley Stunned by the Fulminant Slashed Investments

I actually first read this as alkalizing meaning effecting...

The Next Wave of Superheroes Has Arrived with Astonishing Speed

I actually first read this as alkalizing meaning effecting...

Watch Awesome Kate Halle Go Full Wiming Pro in the Bahamas

I actually first read this as alkalizing meaning effecting...

The Weirdest Places Ashes Have Been Scattered in New Zeeland

I actually first read this as alkalizing meaning effecting...

The Car Insurance Catch that can Double Your Cover in Two Months

I actually first read this as alkalizing meaning effecting...
spot_imgspot_img

Mobileye N.V. (NYSE:MBLY) declared that that it has priced the proposing of 17,127,000 ordinary shares by selling shareholders in a registered public offering at $41.75 a share. The proposing was upsized from the previously released public offering of 145 million ordinary shares. The selling shareholders have also decided the underwriters an option to purchase up to 2,569,050 additional ordinary shares. Subject to customary conditions, the offering is expected to close on or about March 20, 2015. The Company will not receive any proceeds from the offering. Mobileye N.V. (NYSE:MBLY) begun last trade with a price of $42.05 and throughout the trading session climbed at a high of $43.71. The day-trade ended with 2.31% to $43.43. The stock is going forward to its 52 week low with 39.60% and lagging behind from its 52 week high price with -27.95%. MBLY last month stock price volatility remained 4.72%.

Novartis AG (NYSE:NVS) gets EU authorization for Jakavi in polycythemia vera, first targeted therapy approved for patients with this rare blood cancer. The firm reported that the European Commission has approved Jakavi for the treatment of adult patients with polycythemia vera who are resistant to or intolerant of hydroxyurea. Jakavi is the first targeted treatment approved by the European Commission for these patients. Novartis AG (NYSE:NVS) stock price closed at $97.60 with the total traded volume of 1.15 Million shares. Its price to sales ratio ended at 4.92. Its market capitalization is 234.11 Billion

Rovi extends product and patent license contract with Rovi Corporation (NASDAQ:ROVI) declared that it has renewed its interactive program guide product and patent portfolio license contract with Sharp, one of Japan’s top TV manufacturers. The license provides Sharp with access to Rovi’s entertainment discovery capabilities worldwide and Rovi’s G-Guide HTML in Japanese markets for its popular AQUOS brand. Rovi Corporation (NASDAQ:ROVI) has the market capitalization of 1.83 Billion. Shares of firm moved down -2.87% to close at $20.68 with the total traded volume of 2.82 Million. The firm has current ratio of 1.10 for the most recent quarter.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from up to 5 devices at once

Latest stories

spot_img